Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04197349
Recruitment Status : Completed
First Posted : December 13, 2019
Last Update Posted : September 23, 2020
Alder Biopharmaceuticals, Inc.
Information provided by (Responsible Party):
H. Lundbeck A/S

Brief Summary:
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.

Condition or disease Intervention/treatment Phase
Migraine Biological: ALD1910 Biological: Sumatriptan Phase 1

Detailed Description:
This is a first-in-humam, randomized, double-blind, placebo-controlled study in a healthy population. Up to 7 single ascending doses (cohorts 1 to 7) will be studied to determine the safety and tolerability of ALD1910. Approximately 96 healthy male and female participants are planned for the study, 64 for Part A and 32 for Part B.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALD1910, a Humanized Anti-Pituitary Adenylate Cyclase Activating Peptide (PACAP) Monoclonal Antibody
Actual Study Start Date : September 24, 2019
Actual Primary Completion Date : August 19, 2020
Actual Study Completion Date : August 19, 2020

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Migraine
Drug Information available for: Sumatriptan

Arm Intervention/treatment
Experimental: Part A Cohort 1-8
ALD1910/Placebo; Single Dose IV infusion on Day 1
Biological: ALD1910
Single Dose IV infusion

Experimental: Part B Cohort 9
ALD1910/Placebo+Sumatriptan; Single Dose IV infusion on Day 1
Biological: ALD1910
Single Dose IV infusion

Biological: Sumatriptan
Single dose subcutaneous injection

Experimental: Part B Cohort 10
ALD1910/Placebo; Single dose subcutaneous injection on Day 1
Biological: ALD1910
Single dose subcutaneous injection

Primary Outcome Measures :
  1. Number of participants with treatment-emergent adverse events [ Time Frame: From dosing to week 20 ]
    Safety and tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, ECG parameters)

Secondary Outcome Measures :
  1. Area under the serum concentration-time curve (AUC(0-T)) [ Time Frame: From dosing to week 20 ]
  2. Peak serum concentration (Cmax) [ Time Frame: From dosing to week 20 ]
  3. Clearance (Cl) [ Time Frame: From dosing to week 20 ]
  4. Immunogenicity [ Time Frame: From dosing to week 20 ]
    Number of anti-ALD1910 antibodies (ADA) and characterization of anti-ALD1910 ADA positive responses for neutralizing activity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male or female
  2. All female subjects must have a negative pregnancy test result and subjects to use of adequate contraception for the duration of the study.
  3. Body Mass Index (BMI) between 18.0 and 30.0 kg/m2, and a total body weight of 50 to 100 kg inclusive.

Exclusion Criteria:

  1. Use of prescription meds, nutritional supplements, OTC medications.
  2. New or unusually strenuous exercise for the duration of the trial.
  3. Current or previous drug or alcohol abuse.
  4. Current, or previous smoker within 12 weeks prior to screening. Causal or social smokers are allowed.
  5. Previous treatment or clinical trial with a monoclonal antibody 6 months prior to screening.
  6. Current participation in any clinical research study.
  7. ECG QTcF greater than or equal to 450 msec.
  8. Greater than 6.4% glycosylated hemoglobin (HgbA1c) at screening
  9. Fasting blood glucose greater than or equal to 126 mg/dL (7 mmol/L) at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04197349

Layout table for location information
Nucleus Network Pty Ltd
Melbourne, Australia
Sponsors and Collaborators
H. Lundbeck A/S
Alder Biopharmaceuticals, Inc.
Layout table for investigator information
Study Director: Email contact via H. Lundbeck A/S
Layout table for additonal information
Responsible Party: H. Lundbeck A/S Identifier: NCT04197349    
Other Study ID Numbers: ALD1910-CLIN-001
18902A ( Other Identifier: H. Lundbeck A/S )
First Posted: December 13, 2019    Key Record Dates
Last Update Posted: September 23, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Vasoconstrictor Agents
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs